Board of Directors and management of Prostatype Genomics AB enter into agreements regarding lock up
Prostatype Genomics AB (“Prostatype” or “the Company”) hereby announces that members of the Board and management of the Company have entered into agreements regarding prolonged lock up of their holdings in the Company. The lock up refers to 100 percent of each of the parties’ holdings, for a period lasting until the 30[th] of April 2022.In connection with the IPO of Prostatype, members of the Board, as well as management and other shareholders entered into agreement regarding lock up. These agreements expire on the 3[rd] of November 2021, which is 12 months after the first day of trading in